Search
forLearn
5 / 13 resultslearn Metformin
diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Minoxidil
An essential vasodilator with some anti-androgenic effects, has excellent safety record
learn Baricitinib
JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
Research
5 / 1000+ results
research Prioritizing Susceptibility Genes for the Prognosis of Male-Pattern Baldness with Transcriptome-Wide Association Study
The research identified genes linked to male-pattern baldness and potential drug targets for treatment.
research Study of the Interaction Between Self-Assembling Peptide and Mangiferin and In Vitro Release of Mangiferin From In Situ Hydrogel
RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.
research Turmeric Essential Oil Constituents as Potential Drug Candidates: A Comprehensive Overview of Their Individual Bioactivities
Turmeric essential oil compounds have potential as safe, effective drugs.
research A Simple Decision Tree for Identifying Early Oral Drug Candidates With Likely Pharmacokinetic Nonlinearity by Intestinal CYP3A Saturation
The decision tree can predict drug absorption issues with good accuracy but needs more validation and adjustments for other factors.
research Discovering Hair Loss Treatments That Increase The Wnt/Beta-Catenin Signaling Pathway By High-Throughput Screening
Aminoacridine and Abemaciclib, especially combined with Minoxidil, show promise for treating hair loss.
Community Join
5 / 1000+ results
community The story of RU58841/ PSK3841
by
Typical-Promise-3001
in Research
622 upvotes
1 year ago RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community We should actually be hopeful for these recent new developments
AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community How many years can we expect PP405 to be on the market
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
community Getting PP405. Now…. or as soon as possible
People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.